home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences

Search

 
  STRUCTURE-BASED DRUG DESIGN  
  November 29, 2001

Biotechnology

 
     
  Cambridge Healthtech Institute, The Marriott Cambridge Hotel, Cambridge, MA
April 18-19, 2002


Structure-Based Drug Design is based on a firm understanding of molecular recognition between active site groups and interacting molecules and is a strategy that has become an integral part of modern drug discovery. For the past ten years, combinatorial chemistry and diversity-based high-throughput screening were the approaches of choice for lead identification while computational methods were employed predominantly in lead optimization activities. Due to the recent volume and pace at which the 3-D structures of protein targets and their co-crystals have been made available, coupled with advances in computation tools, Structure-Based Drug Design has become a tool for lead generation as well as for optimization. Computational approaches to lead identification and design show many advantages over diversity-based, high-throughput screening, including reduced reagent storage and handling of large libraries, lowering of false positives often associated with HTS, and the ability to find low-molecular-weight leads even when HTS fails. However, there is little doubt that the greatest advances in drug discovery will be achieved by combining the strengths of computational and combinatorial chemistry/HTS strategies. This conference will cover the latest advances in Structure-Based Drug Design methodologies including flexible, faster docking techniques, virtual screening and library design, and target/structure focused combinatorial chemistry and will highlight specific gene-to-lead, preclinical, and clinical case examples. Anyone interested in advancing Structure-Based Design as a tool for drug discovery should attend this event.

 
 
Organized by: Cambridge Healthtech Institute
Invited Speakers: Advisors

Dr. David Bailey, De Novo Pharmaceuticals Ltd.
Dr. Christian Lemmen, BioSolveIT GmbH
Dr. Mark Murcko, Vertex Pharmaceuticals, Inc.
Dr. Tomi K. Sawyer, ARIAD Pharmaceuticals, Inc.
Dr. Brian Shoichet, Northwestern University
 
Deadline for Abstracts: March 15, 2002
 
Registration: http://www.healthtech.com/2002/sbd/reg.htm
E-mail: fvargus@healthtech.com
 
  Posted by:   Frederick Vargus  
Host: wks253.healthtech.com
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2001 HUM-MOLGEN. All rights reserved. Liability and Copyright.